Publications by authors named "Tamam Abdul-Ghani"
Article Synopsis
- The study aimed to assess how well 1-hour plasma glucose (PG) levels during an oral glucose tolerance test (OGTT) can predict the risk of developing prediabetes in individuals with normal glucose tolerance after 7.5 years.
- Out of 1,557 participants, about 24.7% progressed to prediabetes, with higher 1-hour PG levels correlating to increased risk; specifically, those with levels above 155 mg/dL showed greater progression rates.
- The findings suggest using a cut-off point of 120 mg/dL for 1-hour PG to identify individuals at risk, coining the term "pre-prediabetes" for those who show significant insulin resistance and
The influence of smoking on the efficacy of a single-dose methotrexate treatment for ectopic pregnancy.
Int J Gynaecol Obstet
March 2025
Article Synopsis
- Ectopic pregnancy (EP) affects about 2% of all pregnancies and can be treated with methotrexate (MTX) or surgery, but the effectiveness of single-dose MTX has been declining.
- This study analyzed 299 EP patients treated with MTX from 2001 to 2021 to identify factors linked to treatment failure, focusing on smoking.
- Results showed that higher initial β-hCG levels (>1500 mIU/mL) and smoking significantly increased the likelihood of needing surgical intervention after MTX, suggesting that these factors could hinder the success of single-dose treatment.
Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost-effectiveness of day 1-7 β-hCG measurements.
Int J Gynaecol Obstet
September 2024
Objective: The aim of the present study was to compare accuracy, safety and cost-effectiveness of three β-hCG measurements protocols, applied in managing ectopic pregnancies (EP) with methotrexate (MTX): (1) day 1 to 7 β-hCG levels, (2) day 1 to 4 β-hCG levels and (3) day 4 to 7 β-hCG levels.
Methods: Cost-minimization analysis (CMA) based on a retrospective study of patients treated with single-dose MTX for EP, was evaluated at a single institution between January 2001 to May 2021. Successful MTX treatment was defined as no surgical intervention.
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
Diabetes Obes Metab
September 2022
Aim: To examine the efficacy of glucose-lowering medications in subgroups of patients with type 2 diabetes mellitus (T2DM).
Research Design And Methods: Cluster analysis was performed in participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study and the Qatar study using age, body mass index (BMI), glycated haemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β). Participants also underwent an oral glucose tolerance test with measurement of plasma glucose, insulin and C-peptide concentrations to derive independent measures of insulin secretion and insulin sensitivity.
Objective: To develop a model for the prediction of type 2 diabetes mellitus (T2DM) risk on the basis of a multivariate logistic model and 1-h plasma glucose concentration (1-h PG).
Research Design And Methods: The model was developed in a cohort of 1,562 nondiabetic subjects from the San Antonio Heart Study (SAHS) and validated in 2,395 nondiabetic subjects in the Botnia Study. A risk score on the basis of anthropometric parameters, plasma glucose and lipid profile, and blood pressure was computed for each subject.
Role of glycated hemoglobin in the prediction of future risk of T2DM.
J Clin Endocrinol Metab
August 2011
Aim: The aim of this study was to assess the predictive power of glycated hemoglobin (HbA1c) for future type 2 diabetes risk.
Research Design And Methods: Six hundred eighty-seven subjects who were free of type 2 diabetes mellitus (T2DM) participated in the study. Each subject received a 75-g oral glucose tolerance test at baseline and 624 received a repeat oral glucose tolerance test after 3.
Objective: To assess the efficacy of 1-h plasma glucose concentration and the metabolic syndrome in predicting future risk of type 2 diabetes.
Research Design And Methods: A total of 1,611 subjects from the San Antonio Heart Study, who were free of type 2 diabetes at baseline; who had plasma glucose and insulin concentrations measured at time 0, 30, 60, and 120 min during the oral glucose tolerance test (OGTT); and who had their diabetes status determined with an OGTT after 7-8 years of follow-up, were evaluated. Two models, based on glucose tolerance status, 1-h plasma glucose concentration, and presence of the metabolic syndrome, were tested in predicting the risk for type 2 diabetes at 7-8 years of follow-up.